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Inositol transporterThe cyclic polyol myo-inositol is a key molecule in many different metabolic pathways among all
organisms; in addition, it is fundamental for osmotic balance in the mammalian brain. This review
sums up inositol transporters from eukaryotic organisms, elucidating their vital role in regulating
the intracellular distribution and uptake of inositol. They can be divided into two groups according
to their transport mechanisms: (1) sodium ion coupled inositol transporters that belong to the
Solute Carrier Families 5 and 6-like Superfamily and, (2) proton coupled inositol symporters that
are members of the Major Facilitator Superfamily. Intriguingly members of both families offer
promising targets for medical treatment of a variety of diseases.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Myo-inositol is an important component of metabolic pathways.
Its biosynthesis pathway is conserved among all organisms and
starts with the conversion of D-glucose-6-phosphate to L-inositol-
1-phosphate. This reaction is catalysed by the myo-inositol-
phosphate-synthase. Dephosphorylation of L-inositol-1-phosphate
by myo-inositol-monophosphatases results in myo-inositol.
Besides myo-inositol, eight inositol stereoisomers exist (D-chiro-,
L-chiro-, scyllo-, cis-, neo-, muco-, epi- and allo-inositol), but only
seven of them occur naturally [23] (Fig. 1). However, myo-inositol
is the most frequent inositol stereoisomer playing a crucial role in
all organisms.
Myo-inositol is the structural basis of phosphatidylinositol, a
membrane compound that in turn serves as educt for the
synthesis of phosphorylated derivatives, the phosphoinositides.
Phosphatidylinositol can be phosphorylated at position D-3, -4
and -5 of its inositol ring, giving rise to a variety of phosphoinositide
stereoisomers. Phosphatidylinositol-4,5-bisphosphate is probably
the most well-known due to it being the precursor for the second
messenger inositol-1,4,5-trisphosphate. The spectrum of identiﬁed
phosphoinositides is yet incomplete, but for all analysed isomers
additional functions, besides being a structural part of membranes,
were assigned so far. Phosphoinositides are, for example, involved
in signal transduction, membrane trafﬁcking, immune cell func-
tions, chemotaxis and regulation of cytoskeletal dynamics [90,95,5].
There is a multitude of further compounds containing myo-
inositol as an integral part, but inositol itself plays a vital role aswell. It is, for example, essential for the osmoregulation in mam-
malian brain, liver and the renal medulla to protect cells from
the negative impact of hyperosmolality [91,33,36]. Among other
osmolytes, inositol serves to maintain the osmotic balance
between the respective tissue and its surroundings [14].
Accordingly, myo-inositol and methylated inositol derivatives,
e.g., pinitol, are used by some plant species as compatible solutes
that prevent cell damage under salt, cold and drought stress
[16,85]. A sixfold phosphorylated inositol derivative, inositol
hexakisphosphate, also known as phytate, is an important storage
form for phosphate, inositol and also complexes bivalent cations
in plant seedlings [53].
Inositol transporters are responsible for uptake and intracellular
distribution of inositol and were identiﬁed in bacteria, protozoa,
fungi, plants and animals. According to their transport mechanism
they can be classiﬁed into two groups: sodium ion coupled and pro-
ton coupled inositol transporters, respectively. Their physiological
role and importance for applied medical science are summarised.
2. Sodium ion coupled inositol transporters
In 1992 the ﬁrst Na+-coupled inositol transporter was identiﬁed
in Madin–Darby canine kidney (MDCK) cells, as the transporter
responsible for accumulation of myo-inositol in kidney cells
exposed to hypertonic medium. The protein was characterised in
Xenopus oocytes and showed strong similarity to Na+/glucose
transporters [45]. The so-called SMIT (Sodium/Myo-Inositol
Transporter; later re-named in SMIT1 after discovery of a second
Na+-coupled inositol transporter) was soon found also in rat
[104], human [7] and mouse [58]. The respective gene for SMIT1,
SLC5A3, belongs to the Solute Carrier Family 5 (SLC5A) [7]. The
Fig. 1. Structural formulas of inositol stereoisomers. Inositols shown in grey (epi-
and allo-inositol) do not occur naturally.
1050 S. Schneider / FEBS Letters 589 (2015) 1049–1058human SLC5A-family consists of eleven members, including the
Na+/glucose cotransporter SGLT1 and further Na+-coupled trans-
port proteins, all with 14 predicted transmembrane domains
[101] (Fig. 2A).
Using primers against a conserved sequence motif, another
member of the Solute Carrier Family 5, SLC5A11, was cloned from
rabbit in 1994 and its gene product designated rkST1 [39]. It took
several years until this protein was also characterised as Na+-cou-
pled inositol transporter and was thus renamed in SMIT2. On
amino acid level, SMIT2 shows 49% and 43% sequence identity to
SGLT1 and SMIT1, respectively [18]. Fig. 3 shows a phylogenetic
tree for SMIT1 and SMIT2 proteins isolated from several mammals.
Both genes encoding Na+-coupled inositol transporters show
similar expression patterns. SLC5A3, encoding SMIT1, is expressedFig. 2. Protein model for human SMIT1 and postulated splice variants. (A) SMIT1 model
(http://www.cbs.dtu.dk/services/TMHMM/) [44]. (B and C) Models for SMIT1 splice varian
was used to indicate the divergent C-termini of SMIT1-2 and SMIT1-3.in kidney, brain, placenta, pancreas, heart, skeletal muscle and lung
[7]. SLC5A11, encoding SMIT2, shows high expression in kidney,
heart, skeletal muscle, liver and placenta, and is weakly expressed
in the brain [76]. Since both proteins are located in the plasma
membrane [27], further studies focused on investigating functional
redundancy and potential differences between SMIT1 and SMIT2.2.1. Transport characteristics of sodium ion coupled inositol
transporters
SMIT1 activity was ﬁrst analysed by heterologous expression of
canine SLC5A3 in Xenopus oocytes (see Table 1 for transport charac-
teristics of SMIT1 and SMIT2 analysed in heterologous systems). Its
preferred substrate is myo-inositol (Km = 55 lM), yet scyllo-inositol
induced similar currents [37]. SMIT2 accepts D-chiro-inositol
(Km = 130 lM) as well as myo-inositol (Km = 120 lM) [18]. The
physiological substrate of SMIT2 is supposed to be myo-inositol as
the concentration of D-chiro-inositol within the plasma is rather
low [18]. Both transporters show only a low afﬁnity for glucose with
aKm value of50 mMfor SMIT1 and30mMfor SMIT2 [37,18,4,49].
L-Fucose is only transported by SMIT1, but not SMIT2, and was
shown to inhibit in high concentrations myo-inositol transport in
competitor experiments [37,18,10]. D-Chiro-inositol competes with
myo-inositol in SMIT2-mediated transport and has been used as a
speciﬁc inhibitor of SMIT2 but not SMIT1 in non-heterologous sys-
tems. L-Fucose and D-chiro-inositol therefore offer a good possibil-
ity to distinguish between SMIT1 and SMIT2 activity in vivo when
both transporters are present [10,4,46,11,28].
Myo-inositol transport increased after downregulation of pro-
tein kinase C activity and decreased after activation of protein
kinase A in cultured human ﬁbroblasts as well as in MDCK cells,
indicating a posttranslational regulation of the inositol uptake sys-
tem by phosphorylation [71,29].
Analysis of a potential impact of the serum- and glucocorticoid-
inducible kinase SGK1 on SMIT1 activity revealed that phos-
phorylation of SMIT1 by SGK1 and closely related protein kinases
activates myo-inositol transport by increasing the abundance of
SMIT1 within the plasma membrane. As SGK1 gene expression iswas generated using TMHMM Server v. 2.0 prediction for transmembrane domains
ts SMIT1-2 and SMIT1-3 are modiﬁed after [70]. Green and blue colour, respectively,
Fig. 3. Phylogenetic tree of mammalian sodium ion coupled inositol transporters
(SMIT1, SMIT2) and human sodium ion coupled glucose transporter (SGLT1). Tree
was created using ‘‘one click’’ mode from Phylogeny.fr [20]; branch length is
proportional to the number of substitutions per site. Protein accessions: Bos taurus
SMIT1: P53793, SMIT2: Q3ZC26; Canis lupus familiaris SMIT1: P31637; Homo
sapiens SGLT1: P13866, SMIT1: P53794, SMIT2: Q8WWX8; Mus musculus SMIT1:
Q9JKZ2, SMIT2: Q8K0E3; Oryctolagus cuniculus SMIT2: Q28728; Rattus norvegicus
SMIT2: Q9Z1F2; Sus scrofa SMIT2: A8I1B9.
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S. Schneider / FEBS Letters 589 (2015) 1049–1058 1051also induced by hypertonicity, this offers a further mechanism to
regulate myo-inositol import during high osmolarity [43].
An additional regulation of SMIT activity at protein level by
interaction with the a subunit KCNQ1 and the b subunit KCNE2
of potassium channels was shown very recently [1]. Coexpression
of SMIT1 and KCNQ1–KCNE2 or a constitutively active KCNQ1
mutant in Xenopus oocytes inhibits myo-inositol uptake mediated
by SMIT1 but not SMIT2, while coexpression of a constitutively
active KCNQ1 mutant with SMIT1 or SMIT2 inhibits transport
activity of both inositol transporters. Vice versa, channel activities
of KCNQ1 and KCNQ1–KCNE2 were enhanced by SMIT1, but sup-
pressed by SMIT2. Interactions between SMIT1/2 and potassium
channel subunits provide multiple potential feedback mechanisms
to control cell signalling and homeostasis [1].
A recent study on SMIT2 transport activity conﬁrmed the earlier
postulated 2:1 stoichiometry for Na+/myo-inositol cotransport
[18,12] and led to a very detailed ﬁve-state model including bind-
ing of Na+ ions and a turnover rate of 21 s1. In the ﬁrst state, the
SMIT2 binding sites for Na+ and myo-inositol are only accessible
from the extracellular space. Na+ ions bind ﬁrst, initiating the next
state that allows the binding of myo-inositol. Myo-inositol attach-
ment induces a reorientation of the transporter, thereby closing
the extracellular gate. The intracellular gate is opened during the
third state and the substrates are released into the cell. The next
two states are deﬁned by closing the intracellular gate and opening
the extracellular gate, thus restoring the starting point [80].
2.2. SMIT1: expression and gene structure
SMIT1 is a main actor in mammalian osmoregulation by
accumulating myo-inositol in kidney and brain. The expression of
the SLC5A3 is upregulated under hypertonic stress and high
osmolality [45,104,103]. Multiple tonicity-responsive enhancers
are distributed within a 50 kbp 50-ﬂanking region of the SMIT1
gene [75]. Hypertonicity-induced expression of SLC5A3 is regulated
by the transcription factor TonEBP (Tonicity-responsive Enhancer
Binding Protein). TonEBP expression itself is upregulated under
hypertonic conditions, resulting in an increased amount of
TonEBP protein and its translocation to the nucleus [60,29,63].
Studies on TonEBP knockout mice showed that TonEBP is in fact
the key regulator of SMIT1 expression: no SMIT1mRNA was detect-
able in mice missing the TonEBP gene and furthermore, these
knockout mice show the same phenotype as described for SMIT1
knockout mice [87].
While the regulation of SMIT1 gene expression is well estab-
lished, the gene structure of SLC5A3 is under discussion. It has been
postulated that it possesses one [7,58], two [56,15] or even ﬁve
exons [69,70], respectively. The ﬁve-exon model was proposed
1052 S. Schneider / FEBS Letters 589 (2015) 1049–1058due to the discovery of differentially spliced mRNAs. One splice
variant encodes the human SMIT1 protein containing 14
transmembrane helices, while two other variants, SMIT1-2 and
SMIT1-3, encode SMIT1 isoforms without the last transmembrane
domain but with different C-Termini (Fig. 2B and C). These iso-
forms were analysed in Xenopus oocytes and displayed different
transport activities for myo-inositol compared to SMIT1. They also
possess new potential phosphorylation sites that offer additional
points of regulation [70].
Recent studies revealed that the SLC5A3 gene encoding SMIT1 is
on the same gene locus as the gene coding for the mitochondrial
ribosomal protein subunit 6 (MRPS6) [13]. It was shown that
SLC5A3 and MRPS6 share parts of exon 1 and possibly of the pro-
moter region [32,13]. Exon 2 and 3 of the MRPS6 transcript corre-
spond to the postulated exon 4 and 5 of the alternatively spliced
SMIT1 mRNAs, which suggests that these mRNAs might be tran-
scripts encoding MRPS6 instead of SMIT1 isoforms [13].
2.3. The role of SMIT transporters in Down syndrome, Alzheimer’s
disease and bipolar disorder
Down syndrome is caused by the presence of an extra copy of
genes on the long arm of chromosome 21. As SLC5A3 is located
on band q22 on chromosome 21 SMIT1 was soon suspected to be
involved in Down syndrome [7,56]. Down syndrome individuals
possess elevated myo-inositol levels in brain and cerebrospinal
ﬂuid that can already be detected in foeti during pregnancy
[86,8,48,79].
The murine SLC5A3 gene localises to the telomeric region of
chromosome 16, which is syntenic to human chromosome
21q22. Murine trisomy 16 is lethal in the perinatal period, but
Ts65Dn mice which are trisomic only for a segment of chromo-
some 16, can be used as a model system for Down syndrome.
Like their human counterparts, these mice have elevated myo-
inositol levels in the brain due to the third copy of SMIT1 [58,78].
Down syndrome individuals have a higher risk of developing
Alzheimer’s disease and display, when suffering from Alzheimer,
even higher brain myo-inositol concentrations than Down syn-
drome individuals without Alzheimer’s disease. This implicates
also a potential role for SMIT1 in Alzheimer’s disease [48].
Nevertheless, SMIT1 might also be helpful against Alzheimer.
Scyllo-inositol is more and more under discussion being a potential
drug against senile dementia. In the mouse model it inhibits the
aggregation of amyloid b peptides, which is regarded as a key
molecule in Alzheimer’s disease [57,55,88] and improves learning
and memory in senile mice [72]. Its import into brain cells is main-
tained by SMIT1, and studies showed that SLC5A3, encoding SMIT1,
is in fact expressed in target regions for medication within the
brain, at least in the mouse model [28].
The absence of SLC5A3 gene product is lethal under normal con-
ditions. Mice lacking SMIT1 die due to respiratory failure shortly
after birth. Death can be prevented by addition of myo-inositol to
the drinking water of mother mice during pregnancy. However,
surviving Slc5a3 knockout mice exhibit myo-inositol depletion in
brain, kidney, skeletal muscle and liver and in addition show sev-
ere abnormalities in peripheral nerves, sciatic nerve and bones
[9,15,13,19].
These pleiotropic effects underline the importance of SMIT1
activity, although the mechanism for the impact of altered SMIT1
expression is still under discussion [13].
It was postulated that myo-inositol depletion might lead to
altered levels of phosphoinositides, which causes impaired vesicle
trafﬁcking and disturbed phosphoinositide-dependent signalling
[9,15]. However, phosphatidylinositol, ﬁve- and sixfold phos-
phorylated inositols and the second messenger inositol-1,4,5-
trisphosphat concentrations did not vary between Slc5a knockoutand wild type mice [6,13,19]. Nevertheless, the inositol depletion
hypothesis had beenwell accepted for a long time as an explanation
for the way lithium and othermood stabilisers work in treatment of
bipolar disorder [38]. Lithium inhibits myo-inositol-monophos-
phatase and therefore recycling of phosphorylated inositols to
myo-inositol [24]. Also SMIT1 activity is inhibited by lithium, val-
proate and carbamazepine, but as SMIT1 seems not to be the pri-
mary target of these mood stabilisers, the role of inositol
transporters in bipolar disorder remains to be elucidated [54,96].
Na+-coupled inositol transporters were so far only identiﬁed
and characterised in mammals. In contrast to that, proton coupled
inositol transporters can be found among all living organisms.3. Proton coupled inositol transporters
All proton coupled inositol transporters identiﬁed so far belong
to the Major Facilitator Superfamily. The nomenclature varies, as
there are different abbreviations in use (HMIT, INT, ITR, MIT,
MITR), but they all stand for H+/myo-inositol transporter. Table 2
gives an overview on transport characteristics of proton coupled
inositol transporters.3.1. HMIT: a mammalian H+/inositol transporter
The ﬁrst mammalian H+/myo-inositol transporters, from human
and rat, were identiﬁed in 2001 via an EST screen [92]. HMIT1 is
encoded by a member of the SLC2 gene family, SLC2A13. SLC2A13
is predominantly expressed in the brain and its expression is
induced under hypertonic conditions [92,42]. The HMIT protein
shows the same topology as other SLC2 family members: twelve
transmembrane domains, an enlarged loop between the sixth
and seventh transmembrane domain and N- and C-terminus
located within the cytoplasm [94,62].
Rat HMIT was analysed in Xenopus oocytes and shown to be a
H+/myo-inositol symporter with a Km of 100 lM. Competitor
experiments were used to identify additional substrates. Scyllo-,
chiro- and muco-inositol are also accepted by HMIT, while
monosaccharides such as glucose or fructose are not. It was neces-
sary to study a mutated HMIT protein for analysis in oocytes as the
native HMIT protein contains a potential endoplasmic reticulum
retention signal, as well as a dileucine signal for internalisation
within the N-terminus and a C-terminal tyrosine-based internal-
isation motif. Maximal plasma membrane localisation in oocytes
was achieved by mutating all three motifs [92].
The existence of these motifs and the necessity to mutate
them for analysis pointed to a rather non-plasma membrane
localisation of HMIT in vivo. In fact, its localisation is discussed
controversially. Uldry et al. showed that HMIT is present in intra-
cellular vesicles, but can appear on the cell surface in a P12 cell
culture. This relocalisation is triggered by cell plasma membrane
depolarisation, protein kinase C activation or increased intra-
cellular Ca2+ concentrations [93]. In contrast to this, Di Daniel
et al. observed HMIT localisation only at the Golgi apparatus
and could not detect any HMIT-mediated myo-inositol uptake
in isolated neurones [21]. On the other hand Fu et al. demon-
strated that myo-inositol uptake in isolated astrocytes is
mediated by HMIT under physiologically relevant myo-inositol
concentrations which points to at least a partial localisation of
HMIT within the plasma membrane [30]. The ambiguous results
for subcellular localisation of HMIT might be due to the different
cell systems used for analysis.
Independent of its subcellular localisation HMIT could play a
role in Parkinson disease as studies revealed that SLC2A13 seems
to be a Parkinson related gene [31,81]. A direct impact of HMIT
on Parkinson has so far not been shown.
Table 2
Substrate analysis of proton coupled inositol transporters. Red background: transporters from the animal ﬁeld; green background: plant transporters; blue background: fungal
transporters; yellow background: protozoan transport proteins. (See below-mentioned references for further information.)
aA mutated form of HMIT (two putative internalisation motifs and an ER retention signal were removed) was used to achieve plasma membrane localisation.
S. Schneider / FEBS Letters 589 (2015) 1049–1058 10533.2. Yeast inositol transporters
Inositol transporters ITR1 and ITR2 from the model organism
Saccharomyces cerevisiae were identiﬁed by homologous comple-
mentation of a yeast mutant defective in myo-inositol transport.
Both proteins are located in the plasma membrane and accept
myo-inositol with similar afﬁnities (ITR1: Km = 100 lM, ITR2:
Km = 140 lM). However, mainly ITR1 appears to be responsible
for inositol uptake, whereas ITR2 is only of minor importance for
yeast cells. This fact is mirrored both by the high transcript abun-
dance of the ITR1mRNA and by insufﬁcient inositol transport when
only ITR2 is present [67,61]. Transport activity is regulated by aninositol-dependent relocalisation of ITR1. No inositol within the
medium led to a high presence of an ITR1-GFP fusion within the
plasma membrane, while in an inositol containing medium the
GFP ﬂuorescence was redistributed within the yeast cells [61].
Schizosaccharomyces pombe is one of the rare organisms that are
inositol auxotroph by nature [99]. Fission yeast therefore depends
on inositol uptake from its environment. A S. pombe mutant with a
defect in its ITR2 gene is not able to grow on low inositol concen-
trations and growth, mating and sporulation are affected even on
higher inositol concentrations. These effects can be reversed by
overexpression of ITR1, encoding another putative inositol trans-
porter in ﬁssion yeast. ITR1 is not sufﬁcient to complement the loss
1054 S. Schneider / FEBS Letters 589 (2015) 1049–1058of ITR2 under native conditions – a similar situation as in S. cere-
visiae with one inositol transporter of major and one of minor
importance [66].
3.3. Fungal inositol transporters as targets of medical treatment
Candida albicans, normally existing commensally in its human
host, can lead to life-threatening systemic bloodstream infections
in patients with an impaired immune system. C. albicans H+/inosi-
tol transporters aroused attention as potential targets for medical
treatment as inositol is an important growth factor for fungi and
the C. albicans inositol transporters differ kinetically and
pharmacologically from the host’s Na+-coupled inositol trans-
porters. However, deletion of the inositol transport system does
not alter virulence as the need for inositol can be compensated
by inositol biosynthesis. Only double mutations in inositol uptake
and biosynthesis were shown to be lethal [40,17].
A different result was obtained for Cryptococcus neoformans. C.
neoformans is the major cause for fungal meningitis in immuno-
suppressed patients. Compared with most other fungi that have
one or two genes encoding inositol transporters, the C. neoformans
genome contains an unusually large inositol transporter gene fam-
ily with at least ten members. This large number of ITRs probably
mirrors co-evolutionary adaption of C. neoformans to its host, as
human brain contains inositol in abundance, and to environmental
conditions [102]. Two members of the large cryptococcal ITR fam-
ily, ITR1A and ITR3C, are supposed to be the major inositol trans-
porters within this family [98].
Studies using an itr1aD itr3cD double mutant showed that this
mutant has strongly reduced blood–brain-barrier transmission
efﬁciency [51]. Furthermore, mice infected with the mutant C. neo-
formans strain showed a prolonged survival rate compared to those
infected with wild type. This is due to a signiﬁcant reduction in
polysaccharide secretion in the itr1aD itr3cD double mutant that
probably results in differences in cell surface structure and subse-
quently in an altered host response [52]. These ﬁndings reveal that
also cryptococcal inositol transporters are attractive targets of
medication.
3.4. Inositol transport in plants
First plant inositol transporters were identiﬁed in the
common ice plant, Mesembryanthemum crystallinum. Yeast
complementation tests revealed that MITR1, one of three
members of myo-inositol transporters from common ice plant,
does transport myo-inositol, but the transport mechanism was
never analysed in detail [16]. It was hypothesised from MITR
expression data under salt stress, that ice plant MITRs act
Na+-coupled, but this has never been proven [65,16]. Later
analysis of the protein structure and the close relationship to
other proton coupled inositol transporters suggested that also
MITR1, MITR2 and the later discovered MITR3 are proton
coupled inositol symporters [83].
The best characterised plant inositol transporters to date are
those from the model plant Arabidopsis thaliana. The AtINT family
consists of four members, from which only three genes, AtINT1,
AtINT2 and AtINT4, encode a functional protein. AtINT3 was shown
to be a pseudogene [84]. AtINT2 and AtINT4 are plasma membrane
localised in planta and their transport characteristics were
analysed in Xenopus oocytes. Both were shown to be H+/inositol
symporters with AtINT2 transporting myo-inositol > scyllo-
inositol > chiro-inositol and AtINT4 prefering chiro-inositol >myo-
inositol scyllo-inositol. Km values for myo-inositol were deter-
mined and identiﬁed AtINT2 as the transport protein with lower
afﬁnity for myo-inositol (Km = 0.95 mM) compared to AtINT4
(Km = 0.24 mM) [83,84].AtINT1 is a tonoplast localised transporter and patch clamp
experiments on isolated wild type and Atint1 knockout vacuoles
revealed that AtINT1 is the only transporter releasing myo-inositol
outof thevacuolar lumen into thecytosol.A transporter that imports
inositol into the vacuole is not known so far. However, the inositol
derivative phytate (inositol hexakisphosphate) is transported either
directly into the vacuole by AtMRP5, an ABC-transporter [64], or
from the lumen of the endoplasmic reticulum via vesicle transport
[35,68]. Furthermore, membrane vesicles are sequestered into the
vacuole during autophagic processes and subsequently degraded
[50].Hence, vacuolar inositol probablyderives fromthedisassembly
of phytate and/or inositol containing membrane compounds [82].
While a knockout of the plasma membrane transporters AtINT2
and AtINT4 does not lead to phenotypic alterations compared to
wild type, Atint1 knockout plants show shorter roots. This can be
complemented by adding myo-inositol to the growth medium.
AtINT1 is important for maintaining the intracellular inositol dis-
tribution and affects seedling development [82]. A C-terminal
acidic dileucine motif is responsible for routing AtINT1 to the tono-
plast [100] (Fig. 4). The targeting of AtINT1 is mediated by adaptor
protein complex AP-1 [97].
AtINT1 on the one andAtINT2 andAtINT4 on the other hand have
different subcellular localisations that are alsomirrored in their pro-
tein structure. AtINT2 and AtINT4 possess an enlarged extracellular
loop between the ninth and tenth transmembrane domain that is
missing in AtINT1 (Fig. 4). This loop contains eight conserved cys-
teins that form a so-called PSI (Plexin/Semaphorin/Integrin) domain
[84,22]. A speciﬁc role in intercellular signalling is suggested as this
PSI domain can be found in all plasma membrane H+/inositol trans-
porters from animals and plants analysed so far but is absent in fun-
gal and endomembrane inositol transporters [22].
In this context the subcellular localisation of MITR1 and MITR2
from M. crystallinum is again in focus. Immunolocalisation in iso-
lated vesicles with antibodies against MITR1 and MITR2 suggested
a subcellular localisation in the tonoplast, but also signals within
the plasma membrane fraction were found [16]. In protein
sequence alignments, MITR1 and MITR2 cluster together with
plasma membrane located INTs (Fig. 5), while a third inositol
transporter from Mesembryanthemum, MITR3, is found within the
clade containing AtINT1 and another recently identiﬁed tonoplas-
tic inositol transporter, AcINT1, from Ananas comosus [3].
The MITR signal in the vacuolar membrane fraction might
therefore derive from the later identiﬁed MITR3, while MITR1
and MITR2 are likely to be plasma membrane proteins [3].
Another recently identiﬁed plant plasma membrane inositol
transporter is MfINT-like from Medicago falcata. MfINT-like seems
to play an important role in adaptation to abiotic stress. MfINT-like
expression is induced by cold and salt stress in Medicago and
tobacco plants overexpressing MfINT-like are more tolerant to
freezing temperatures and can develop more fresh weight when
grown under drought or salt stress [77].
Many more genes coding for putative inositol transporters have
been identiﬁed in a variety of plant species (Rice: [41]; Vine: [2];
Selaginella: [47]; Tomato: [73]) and transport characteristics as
well as physiological roles of the encoded proteins are waiting to
be discovered.
3.5. Inositol transporters of protozoan pathogens
Leishmaniasis is a collective term for different tropical diseases
all caused by different Leishmania species. Drug treatment is often
toxic for the human host and more and more resistances occur
[105].
LdMIT, the only Leishmania donovani myo-inositol transporter,
transports myo-inositol and the cytotoxic inositol analogue 3-ﬂu-
oro-myo-inositol with similar afﬁnities (Km value for myo-
AB
Fig. 4. Models for plant inositol transporters, based on Arabidopsis thaliana AtINT1 and AtINT4. (A) Model for INT1-type proteins. Red and blue coloured amino acids highlight
the C-terminal [D/E]XXXL[L/I]-like acidic dileucine motif. (B) Model for INT4-type proteins. Conserved cysteins within the enlarged extracellular loop that are responsible for
formation of the PSI domain are highlighted in orange. Protein structures modiﬁed after Dotzauer et al. [22].
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and binding compared to the inositol transport system of the
human host offer the chance to use the leishmanian inositol trans-
porter as a potential gate for speciﬁc drug delivery into the patho-
gen [59].
In Trypanosoma brucei, a parasite that causes African sleeping
sickness, a H+/inositol transporter, TbHMIT, was identiﬁed and
shown to be essential for the pathogen’s survival in culture. RNAi
silencing of TbHMIT led to massive reduction of myo-inositol
import, which in turn resulted in depletion of bulk inositol lipids
and death of the parasite. Since myo-inositol uptake is essential
for T. brucei, TbHMIT is a promising drug target [34].
Two transporter systems for inositol were proposed for
Trypanosoma cruzi, causative agent of Chagas’ disease: one that is
active at low inositol concentrations and H+-coupled, and one that
is active at higher inositol concentrations and Na+-coupled [25]. So
far, none of the proposed transport proteins was characterised on
molecular level, and only one candidate gene was found in the
T. cruzi genome [26]. From structural similarities to other H+-cou-
pled inositol transporters it seems likely that this gene is the can-
didate for a H+-coupled transporter [34] (Fig. 5).
Search via BLAST analysis resulted in no hits for a potentialmyo-
inositol-phosphate-synthase gene in the pathogens Toxoplasmagondii and Cryptosporidium parvum. Potential myo-inositol-phos-
phate-synthase genesmight be too different from already identiﬁed
genes to be found via BLAST, but if in fact there is no inositol biosyn-
thesis in these pathogens, theymust rely on inositol transporters as
uptake from the environment is the only source for inositol.
Therefore, ITRs in T. gondii and C. parvum offer good targets formed-
ication [74].
4. Conclusions
Inositol transporters play an essential role in the uptake and
intracellular distribution of inositol, an important key molecule
in many metabolic pathways. Na+/inositol transporters were so
far only identiﬁed in animals, while H+/inositol symporters were
found in all eukaryotic kingdoms. Human inositol transporters,
the Na+-coupled SMITs as well as the H+-dependent HMIT, are of
medical interest due to their role in numerous diseases.
Therefore, it is not surprising that these transporters and their
model counterparts from the animal ﬁeld have been studied
extensively investigating their kinetic functions and physiological
role.
More than 27 million people worldwide are affected by diseases
caused by trypanosomatid parasites, mainly Leishmania or
Fungi
Animals
Protozoa
Plants
VM
VM
PM
PM
PM
Fig. 5. Family tree of eukaryotic H+/inositol transporters. Green background: plant
transporters without PSI domain. Blue background: plant transporters containing a
potential PSI domain. Subcellular localisation of plant inositol transporters analysed
using GFP fusion indicated in red letters. VM = vacuolar membrane; PM = plasma
membrane. Family tree was created with ‘‘one click’’ mode using Phylogeny.fr [20];
branch length is proportional to the number of substitutions per site. Protein
accessions: Ananas comosus INT1: ABO21769; Arabidopsis thaliana INT1: CAJ00303,
INT2: CAJ00304, INT3: CAJ00305, INT4: CAJ00306; Bos taurus HMIT:
NP_001179892; Caenorhabditis elegans HMIT-1.1: CAA16400, HMIT-1.2:
CAA16405, HMIT-1.3: CAA86519; Cricetulus griseus HMIT-like: ERE84815; Homo
sapiens HMIT: Q96QE2; Leishmania donovani MIT: XP_003861159; Leishmania
mexicana MIT: XP_003875880; Medicago falcata INT-like: AHF50208;
Mesembryanthemum crystallinum MITR1: AAF91431, MITR2: AAF91432, MITR3:
AAO74897; Mus musculus HMIT: Q3UHK1; Oryza sativa ITR1: CAD41357, ITR2:
NP_001053292, ITR3: BAC79509; Rattus norvegicus HMIT: Q921A2; Saccharomyces
cerevisiae ITR1: P30605, ITR2: P30606; Schizosaccharomyces pombe ITR1: Q10286,
ITR2: P87110; Solanum lycopersicum INT1: K4C961, INT2: K4CKI1, INT3: K4DHS8,
INT4: K4D649; Trypanosoma brucei MIT: Q385N3; Trypanosoma cruzi MIT:
XP_814419; Vitis vinifera INT1: ADP37179, INT2: ADP37180, INT3: ADP37181.
1056 S. Schneider / FEBS Letters 589 (2015) 1049–1058Trypanosoma species [89]. Protozoan inositol transporters are
potential targets for medication.
Analysis of plant inositol transporters indicated a new strategy
for plants to adapt to abiotic stress. Furthermore, inositol transport
proteins are a suitable tool to study targeting mechanisms of mem-
brane proteins.
In the future it is undisputable that research on inositol trans-
porters will bring further important insights in cell physiology in
eukaryotic organisms.
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